Clinical Trial

Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Tenecteplase (TNK) is the latest generation of specific thrombolytic drugs independently developed in China. This study aims to investigate the thrombolytic efficacy of platelet membrane-coated tenecteplase (PM-TNK) on human ex vivo arterial thrombi, and to explore the inhibitory effects of plasma from patients receiving antiplatelet therapy on its thrombolytic activity, thereby evaluating the future clinical application value of PM-TNK.
Trial Details
NCT Number NCT07712445
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Arterial Thrombosis
Enrollment 24 participants
Start Date 2026-06-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-17